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Background: The CHADS2 score is used to identify AF patients at low risk of stroke and thus unlikely to benefit from oral anticoagulation (OAC), 
but does not adequately discriminate stroke risk in those with a score of 0-1. The CHA2DS2-VASc score improves stroke risk prediction in the overall 
AF population but it is unclear whether it improves risk prediction in those with a CHADS2 score of 0-1. The objective of this study was to evaluate 
the ability of the CHA2DS2-VASc score to discriminate stroke risk in AF patients treated with antiplatelet therapy who had a CHADS2 score of 0-1.
Methods: The AVERROES and ACTIVE trials enrolled patients with AF and at least 1 additional risk factor for stroke: age ≥ 75 years, hypertension, 
diabetes mellitus, heart failure, prior stroke or transient ischemic attack, peripheral arterial disease or coronary artery disease. In the subgroup of 
patients receiving antiplatelet therapy who had a CHADS2 score of 0-1 we determined the incidence of ischemic or unspecified stroke or systemic 
emboli (SSE) according to CHA2DS2-VASc score and assessed the ability of the CHA2DS2-VASc to discriminate risk using C-statistic.
Results: 4,816 patients had a CHADS2 score of 0-1 at study entry. During 11,808 patient years 212 patients experienced SSE (incidence 1.8%/
year, 95%CI 1.6-2.1). Within this group, SSE incidence rates according to CHA2DS2-VASc score were 0.9%/year (95%CI 0.6-1.3) for a score of 1; 
2.0%/year (95%CI 1.6-2.4) for a score of 2; and 2.3%/year (95%CI 1.9-2.9) for a score of 3-4. The C-statistic for the CHA2DS2-VASc score among 
patients with a CHADS2 score of 0-1 was 0.57 (95%CI 0.54-0.59).
Conclusions: The CHA2DS2-VASc modestly improves discrimination of risk of SSE in AF patients with a CHADS2 score of 0-1 treated with 
antiplatelet therapy.
